Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- March 5, 2026
- Completion date
- November 7, 2031
- Enrollment
- 600 (estimated)
- Sites
- 260
Conditions
As the registry lists them; a condition with its own page is linked.